Inmune Bio, Inc.

Inmune Bio, Inc. (ticker: INMB) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of INMB's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. INMB reported $50K in revenue and -$5.41M for the period ending 2025-12-31, with operating cash flow of -$3.40M. Cash and equivalents stood at $21.36M (up 10.5% year-over-year). Total assets of $25.82M exceed total liabilities of $6.19M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.